ADVFN Logo
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Genetic Technologies Ltd

Genetic Technologies Ltd (GENE)

1.70
0.05
(3.03%)
Closed June 23 4:00PM
1.70
0.00
(0.00%)
After Hours: 5:02PM

Empower your portfolio: Real-time discussions and actionable trading ideas.

Key stats and details

Current Price
1.70
Bid
1.65
Ask
4.20
Volume
14,094
1.66 Day's Range 1.72
0.00 52 Week Range 0.00
Market Cap
Previous Close
1.65
Open
1.66
Last Trade
10
@
1.72
Last Trade Time
Financial Volume
$ 23,940
VWAP
1.6986
Average Volume (3m)
-
Shares Outstanding
3,847,219
Dividend Yield
-
PE Ratio
-0.03
Earnings Per Share (EPS)
-3.05
Revenue
10.35M
Net Profit
-11.75M

About Genetic Technologies Ltd

Genetic Technologies Ltd is an Australia-based molecular diagnostics company that offers predictive testing and assessment tools to help physicians proactively manage women's health. The company has developed BREVAGenplus which is a clinically validated risk assessment test for non-hereditary breast... Genetic Technologies Ltd is an Australia-based molecular diagnostics company that offers predictive testing and assessment tools to help physicians proactively manage women's health. The company has developed BREVAGenplus which is a clinically validated risk assessment test for non-hereditary breast cancer. It also provides genetic testing services including medical testing, animal testing, forensic testing, and plant testing. The company markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/ gynecologists (OBGYNs) and breast cancer risk assessment specialists. The majority of the company's revenue is generated from Australia and the United States. Show more

Sector
Gold Ores
Industry
Coml Physical, Biologcl Resh
Website
Headquarters
Melbourne, Victoria, Aus
Founded
1987
Genetic Technologies Ltd is listed in the Gold Ores sector of the NASDAQ with ticker GENE. The last closing price for Genetic Technologies was $1.65. Over the last year, Genetic Technologies shares have traded in a share price range of $ 0.00 to $ 0.00.

Genetic Technologies currently has 3,847,219 shares outstanding. The market capitalization of Genetic Technologies is $346,250 . Genetic Technologies has a price to earnings ratio (PE ratio) of -0.03.

GENE Latest News

Join Genetic Technologies’ Exclusive Live Investor Webinar and Q&A Session on June 27

CHARLOTTE, N.C. and MELBOURNE, Australia, June 21, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (NASDAQ:GENE, ASX:GTG, “Company”, “GTG”, or “Genetic Technologies”), a global leader in...

Genetic Technologies Expands Operational Capacity in North America

CHARLOTTE, N.C., June 18, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and...

GeneType and Stayhealthy Announce Landmark Distribution Agreement for Revolutionary Multi-Risk Test

MELBOURNE, Australia, June 05, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and...

GTG Launches Revolutionary geneType Test covering 100% Risk of Breast and Ovarian Cancer

MELBOURNE, Australia, May 29, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and...

GeneType and Humanise Health host “Know Your Risk” Event

PASADENA, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GeneType”), a global leader in genomics-based tests in health, wellness and...

GTG and ‘Wellworks for You’ sign B2B sales & marketing deal covering 750 employer groups and 2 million U.S. employees

MELBOURNE, Australia, May 06, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and...

Genetic Technologies Announces Closing of US$2 Million Registered Direct Offering

MELBOURNE, Australia, April 23, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE, “Company”, “GTG”, or “Genetic Technologies”), a global leader in guideline-driven...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10000000DR
40000000DR
120000000DR
260000000DR
520000000DR
1560000000DR
2600000000DR

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AREBAmerican Rebel Holdings Inc
$ 0.76
(152.49%)
371.46M
SHCRSharecare Inc
$ 1.365
(76.27%)
56.33M
NXLNexalin Technologies Inc
$ 1.7499
(59.08%)
57.58M
FUFUBitFuFu Inc
$ 6.1209
(56.95%)
2.5M
SPECSpectaire Holdings Inc
$ 0.50
(47.06%)
65.27M
FLFVFeutune Light Acquisition Corporation
$ 2.5502
(-69.75%)
862.38k
FLFVUFeutune Light Acquisition Corporation
$ 2.75
(-66.83%)
16.5k
RWODRedwoods Acquisition Corporation
$ 2.34
(-60.34%)
155.96k
KAVLKaival Brands Innovations Group Inc
$ 1.23
(-57.14%)
4.92M
RWODURedwoods Acquisition Corporation
$ 3.24
(-56.28%)
1.47k
NVDANVIDIA Corporation
$ 126.57
(-3.22%)
658.13M
AREBAmerican Rebel Holdings Inc
$ 0.76
(152.49%)
371.46M
SIRISirius XM Holdings Inc
$ 2.94
(1.38%)
330.66M
AAPLApple Inc
$ 207.49
(-1.04%)
246.38M
NKLANikola Corporation
$ 0.3466
(5.16%)
193.36M

GENE Discussion

View Posts
Monksdream Monksdream 4 weeks ago
GENE under $3
👍️0
BurgerKing82 BurgerKing82 4 months ago
Fascinating how quiet this board is...people do realize less than 3 million OS,right?....This puppy will pop at some point...Imagine if 400-800k or more shares get bought up
👍️0
realtmg realtmg 4 months ago
Took a position
👍️0
Awl416 Awl416 4 months ago
What leaked?
👍️0
Monksdream Monksdream 4 months ago
GENE 10Q 2/27
👍️0
Monksdream Monksdream 4 months ago
GENE under $2
👍️0
Monksdream Monksdream 6 months ago
GENE new 52 week low
👎️ 1 🤡 1 🩳 1
harry crumb harry crumb 6 months ago
Gene is now junk! Sold out this turd for end of year loss. Going nowhere but back under 1$
👍️0
Monksdream Monksdream 7 months ago
GENE new 52 week low
👍️0
zeusgodmd zeusgodmd 7 months ago
Maybe shorts going to cover before split
👍️0
zeusgodmd zeusgodmd 7 months ago
They are going to make a 60 cent stock 60$ seems a little crazy
👍️0
zeusgodmd zeusgodmd 7 months ago
I hope so
👍️0
harry crumb harry crumb 7 months ago
Almost time for this to double
👍️0
zeusgodmd zeusgodmd 8 months ago
Somebody buy this company this is pathetic, but I did buy more today
👍️0
harry crumb harry crumb 9 months ago
Its going to be the next bio dynasty! $$$$$
👍️0
subslover subslover 9 months ago
NP man. This one is a starving wolf with flees. Smells bad too!
👍️0
Invest-in-America Invest-in-America 9 months ago
GENE: Admiral Subs, Orion Fleet Commander!! (SORRY for my belated replies here, but off today behind family matters; but MONSTER THANKS!! Will still toss bucks at some of your picks today, when they lock-in for launch or set-back.)
👍️0
harry crumb harry crumb 9 months ago
This company is the next merck! Enough said, buy em up now an wait it out. We loaded here an still adding
👍️0
subslover subslover 9 months ago
News #2 GENE Positioned at the Forefront of Multi-cancer Clinical Utility Research - MRFF Grant names GTG as sole Industry Partner
Trial to Assess Multi Cancer Genetic Risk Assessment in General Practice
MELBOURNE, Australia, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to announce that a Medical Research Future Fund (MRFF) Genomics Health Futures Mission Grant has been awarded to a group of renowned national and international research and charity organizations. The grant will provide funding for the CASSOWARY Trial: a randomised controlled trial of the clinical utility and cost-effectiveness of a multi-cancer polygenic risk score in general practice. GTG is the National Research Partner for trial which is to be led by Professor Jon Emery.

Highlights:

Results from the trial are expected to change the way risk is assessed and reshape the standard of care in general practice for serious disease.
The trial results will inform future policy including the 5-year goal in the Australian Cancer Plan of using genomics for risk-stratified cancer screening.
Results of this study could lead to a revision of national guidelines and improve risk stratification for four of the most common cancers in Australia; breast, colorectal, prostate, and melanoma.
The study will recruit nearly 600 participants from eight general practices across Victoria.
As the sole industry partner, GTG will receive funding to cover the supply of test kits and the analysis of the sample returned.
The project titled, “The CASSOWARY (CAncer genomic riSk ScOres in primARY Care) Trial: a randomised controlled trial of the clinical utility and cost-effectiveness of a multi-cancer polygenic risk score in general practice”. This is a multi-institutional, multidisciplinary collaborative initiative with internationally recognised experts. Disciplines include academic, general practice and primary care trials, clinical genetics and genetic counselling, genetic/cancer epidemiology, health economics and modelling, biostatistics, implementation science, genomic test development and commercialisation, consumer investigators with lived experience of cancer and associate investigators with expertise in cancer policy with Cancer Australia. The Cassowary Trial is a collaboration between international investigators from GTG (Industry partner), University of Melbourne and Queen Mary University of London, The Royal Melbourne Hospital, Royal Marsden NHS Foundation Trust, and the Daffodil Centre.

The study will recruit a targeted cohort to create high quality evidence about the clinical utility and cost-effectiveness of using cancer polygenic risk scores, such as geneType multi-Test to tailor cancer screening and possible treatment in general practice.

Professor Jon Emery, the lead investigator of this study team, has an established history in genomics in Australian general practice and has been involved in national and international screening and cancer risk assessment guidelines. This funding is one of several trials that he leads, “We look forward to extending our work in the space of polygenic risk score implementation in general practice. Over the years, our team has created a framework for risk-assessment implementation in clinical practice, and with each subsequent study we are building our evidence to support a structured, real-world implementation strategy.”

This multi-year utility trial will focus on the implementation of four of geneType’s multi-Test integrated polygenic risk scores: breast, colorectal, prostate, and melanoma. The trial will assess patient and provider behaviour, and assess the economic impact of the resulting behaviour.

GTG’s Director of Scientific Affairs, Erika Spaeth, a co-investigator of the study said, “We are proud of our academic partnerships and honoured to be a part of the growing body of evidence showing the utility of polygenic risk in clinical care. We look forward to the implementation evidence outcomes that will result from this utility study.”

GTG has a strong history of research partnerships with academic institutions, including the University of Melbourne. The company is committed to its collaborative initiatives that support the evolution of predictive population healthcare. GTG’s CEO, Simon Morriss noted, “This is an important step forward for preventive precision medicine. The results from the Cassowary Trial have the ability to support the clinical utility of geneType multi-Test and even more importantly provide compelling evidence for its’ inclusion into National Guidelines and standard of care. The results from this study will be a major leap forward for geneType.”

Authorised for release by the board of directors of Genetic Technologies Limited.

Enquiries

Investor Relations
Adrian Mulcahy
Automic Markets
M: +61 438 630 411
E: adrian.mulcahy@automicgroup.com.au

About Genetic Technologies Limited

Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE) is a diversified molecular diagnostics company. A global leader in genomics-based tests in health, wellness and serious disease through its geneType and EasyDNA brands. GTG offers cancer predictive testing and assessment tools to help physicians to improve health outcomes for people around the world. The company has a proprietary risk stratification platform that has been developed over the past decade and integrates clinical and genetic risk to deliver actionable outcomes to physicians and individuals. Leading the world in risk prediction in oncology, cardiovascular and metabolic diseases, Genetic Technologies continues to develop risk assessment products. For more information, please visit www.genetype.com
👍️0
subslover subslover 9 months ago
Breakthrough: GeneType for Pancreatic Cancer, Melanoma, and Atrial Fibrillation Cleared for Australian Release
Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) Expands Reach of Revolutionary geneType Multi-Risk Test in Australia: A major advancement towards preventative Healthcare

MELBOURNE, Australia, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (GTG), a pioneering global leader in genomics-based tests focused on health, wellness, and the battle against serious diseases, proudly announces a groundbreaking development. The expanded geneType Multi-Risk Test is now readily accessible for order in Australia, marking a significant milestone in the journey to redefine preventative healthcare.

Early 2023, GTG unveiled the tests in the United States, introducing three additional diseases to the already remarkable geneType Multi-Risk Test platform. Today, with immense pride, we share the news that these innovations, including assessments for Pancreatic Cancer, Melanoma, and Atrial Fibrillation, have been authorized for sale in Australia by National Association of Testing Authority (NATA). This expanded genetic test now offers a comprehensive evaluation of risk for a total of nine individual serious diseases, all extracted from a single, simple saliva sample.

The risk assessment panel revolves around Oncology, Cardiovascular, and Metabolic diseases, covering:

Breast Cancer
Ovarian Cancer
Pancreatic Cancer
Prostate Cancer
Melanoma
Colorectal Cancer
Diabetes
Coronary Artery Disease
Atrial Fibrillation
The approval granted by NATA follows the release in March by the Centers for Medicare & Medicaid (CMS) to offer the enhanced panel in the United States.

The expanded Multi-test panel caters to individuals of diverse ethnic backgrounds, focusing on those over the age of 30. Each of these newly incorporated diseases holds a significant threat to public health, with dire statistics calling for immediate attention.

According to the Australian Institute of Health and Welfare, 2023 is expected to witness approximately 10,639 new cases of melanoma, Australia's third most diagnosed cancer. Pancreatic cancer estimates are even grimmer, projecting 2,355 new diagnoses in 2023, with a staggering 87% mortality rate. Early identification of high-risk individuals for both melanoma and pancreatic cancer offers a vital window for early intervention, potentially saving countless lives.

In the case of atrial fibrillation (AFib), research indicates its impact on approximately 2% of the Australian population, equating to over 500,000 individuals. Detecting AFib early can pave the way for interventions that improve patient outcomes, extend life expectancy, and save lives.

Simon Morriss, CEO of GTG, states, "Securing approval for the expanded version of the Multi-test in Australia underscores GTG's unwavering dedication to lead the world in delivering personalized risk assessments, thereby enabling population wide preventative healthcare for a range of serious diseases."

Authorised for release by the board of directors of Genetic Technologies Limited.

Enquiries

Investor Relations
Adrian Mulcahy
Automic Markets
M: +61 438 630 411
E: adrian.mulcahy@automicgroup.com.au

About Genetic Technologies Limited

Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE) is a diversified molecular diagnostics company. A global leader in genomics-based tests in health, wellness and serious disease through its geneType and EasyDNA brands. GTG offers cancer predictive testing and assessment tools to help physicians to improve health outcomes for people around the world. The company has a proprietary risk stratification platform that has been developed over the past decade and integrates clinical and genetic risk to deliver actionable outcomes to physicians and individuals. Leading the world in risk prediction in oncology, cardiovascular and metabolic diseases, Genetic Technologies continues to develop risk assessment products. For more information, please visit www.genetype.com

https://www.globenewswire.com/newsroom/ti?nf=ODkxOTY4MyM1ODA3MzA2IzIwNTAwMzg=
https://ml.globenewswire.com/media/OGNiZWVkYTQtMzlkYy00ZjIwLTlmNjEtYjE3OTUyODM4YjgyLTEwNjE2MDk=/tiny/Genetic-Technologies-Ltd.png

Source: Genetic Technologies Ltd
© 2023 GlobeNewswire, Inc.
Back to News Headlines
Other Financial Information
Recent News & Disclosure Filings
Recent SEC Filings
👍️0
zeusgodmd zeusgodmd 9 months ago
Harry I hope you right this company should be bought out by Merck or someone with big cancer portfolio
👍️0
harry crumb harry crumb 9 months ago
5$ coming, load now, going to go up
👍️0
harry crumb harry crumb 10 months ago
Breakout coming
👍️0
Monksdream Monksdream 10 months ago
GENE new 52 week low
👍️0
harry crumb harry crumb 12 months ago
Watching this for a big jump
👍️0
1idiotinvestor 1idiotinvestor 1 year ago
I watched the clip on Balancing Act about breast Cancer and "Gene Type". Very good news.
👍️0
zeusgodmd zeusgodmd 1 year ago
Advertising starting only up from here
👍️0
zeusgodmd zeusgodmd 1 year ago
They where going to start selling campaign in us in may will see
👍️0
zeusgodmd zeusgodmd 1 year ago
Stock should be 5 to 10$ by now. Sell company to highest bidder
👍️0
harry crumb harry crumb 1 year ago
This is going to pop big one of these days
👍️0
zeusgodmd zeusgodmd 1 year ago
Have to read up on seeing alpha web site the meeting it’s typed up. Big things planned for marketing in USA. Big meeting in Montreal Canada in May. Buy your shares now and watch. Nice after hours movement
👍️0
zeusgodmd zeusgodmd 1 year ago
Pfizer in talks to buy seagen 30 billion for cancer drugs market too big not to buy gene
👍️0
harry crumb harry crumb 1 year ago
This ticker could be a huge winner! $$$$
The science is looking very promising
👍️0
zeusgodmd zeusgodmd 1 year ago
Moderna in with life edit for gene manipulation matter of til phizer buys this beauty
👍️0
harry crumb harry crumb 1 year ago
Added an holding here
👍️0
SmellMyFinger SmellMyFinger 1 year ago
Not giving financial advice though, right?
👍️0
harry crumb harry crumb 1 year ago
Hold hold add add
👍️0
zeusgodmd zeusgodmd 1 year ago
Phizer or Merck oncology division will buy this out more diagnoses more money they make on chemotherapy. Big boys holding it down I go my shares for the ride
👍️0
zeusgodmd zeusgodmd 1 year ago
Open up that report in new section shows there new path of advertisement and stuff with patents in countries
👍️0
harry crumb harry crumb 1 year ago
3$
👍️0
zeusgodmd zeusgodmd 1 year ago
Let’s see 4 to 6$ today folks big buys and pr blitzing occurring
👍️0
zeusgodmd zeusgodmd 1 year ago
I forgot it was also a ticker going across the screen on mad money last night
👍️0
zeusgodmd zeusgodmd 1 year ago
Share outstanding I have 19 million does not seem like a lot with volume this week
👍️0
zeusgodmd zeusgodmd 1 year ago
Will see the bump at 830
👍️0
zeusgodmd zeusgodmd 1 year ago
These test are usually 2500$ each maybe some don’t know how much money this company is going to make worldwide with new results from Harvard will be a game changer
👍️0
harry crumb harry crumb 1 year ago
This thing could really pop tomorrow, should be very active an agree huge volume may happen
👍️0
saj saj 1 year ago
Bring on the volume!
👍️0
zeusgodmd zeusgodmd 1 year ago
Current buys are people who can buy after hours
👍️0
zeusgodmd zeusgodmd 1 year ago
200 million share day tomorrow
👍️0
saj saj 1 year ago
Hope it continues higher tomorrow AM
👍️0

Your Recent History

Delayed Upgrade Clock